Eight patients rechallenged with lamotrigine after initial exposure which resulted in a skin rash are reported. On reintroduction of the lamotrigine, six of the patients had no recurrence of the rash. Of the other two patients, one had the occurrence of a mild fluctuating and qualitatively different skin rash on rechallenge. The other patient had developed a dose-related rash on initial challenge resulting in a dose reduction. The first attempt to re-increase the dose resulted in reappearance of the rash which again disappeared on dose reduction. However a further attempt to re-increase the dose did not result in reappearance of a rash. It is suggested that patients who experience a rash but good therapeutic response to lamotrigine might be considered for re-dosing.
INTRODUCTION
Lamotrigine is a novel and effective 1 anticonvulsant, indicated for add-on therapy 2 which has been associated with skin rashes, leading to withdrawal, in up to 2% of patients challenged 2.
Skin rash is the commonest adverse reaction leading to withdrawal 3 and rechallenge in cases of known hypersensitivity is currently contraindicated 2. We present eight cases in whom successful rechallenge occurred after apparent hypersensitivity.
CASE HISTORIES Case 1
Case 1 is a 28-year-old male with a 17-year history of generalized epilepsy. He had up to 30 atypical absences daily and tonic-clonic seizures every alternate day. From day 2 he had no further seizures but on day 11 developed a generalized papular rash involving his arms, shoulders and back but not mucosae. It was associated with pyrexia, nausea, malaise, depression of platelets from 217 to 160 × 10s/1 and reduction of white cell count from 8 to 3.6 × 109/1. Lamotrigine was discontinued on day 13 and by day 17 the rash was fading and haematological parameters normalizing. He was rechallenged 18 months later, commencing at 12.5mg daily on day 1, 25 mg daily on day 6, 25 mg b.d. on day 11 and finally 75 mg daily, in divided doses, from day 25. Follow-up over the succeeding 15 months showed no recurrence of rash or other adverse reaction. He was seizure-free from day 1 of rechallenge.
Case 2
Case 2 is 14-year-old female with 13-year history of localization-related epilepsy. She was experiencing about six seizures per week and took carbamazepine 600mg daily. There was a history of sodium valproate idiosyncracy.
Lamotrigine was introduced at 100mg daily and increased to 200mg daily 2 weeks later. Eleven days after the dose increment she developed a rash over her face and eyelids. It was noted that the rash was worse just after taking the tablets in the morning and then improved as the day progressed. Lamotrigine was stopped 2 days later and the rash resolved. She was rechallenged 20 months later with 12.5 mg daily, increased to 25 mg daily after 2 weeks and then doubled at bi-monthly intervals until she was on 200 mg daily. There was no recurrence of rash but rechallenge was therapeutically ineffective and lamotrigine was withdrawn 1 year later.
Case 3
Case 3 is a 9-year-old female with 3-year history of localization-related epilepsy and experiencing three to four seizures daily. She was on no medication having previously been tried with ethosuximide, carbamazepine and sodium valproate without effect. Phenytoin, although therapeutically effective, on challenge and rechallenge had casued a widespread itchy macular rash.
Lamotrigine was introduced at 12.5mg every alternate day but had to be withdrawn after 10 days because of development of an itchy rash on the inside of her thighs. Rash was unassociated with any haematological disturbance.
She was rechallenged 2 months later at an initial dose of 0.5mg every alternate day, which was slowly built up over 6 months to 12.5 mg daily. The dose was then more quickly increased to 75 mg daily over the following 4 months. There was no recurrence of rash and seizure frequency reduced to less than one a day.
Case 4
Case 4 is an ll-year-old male with 9-year history of symptomatic localization-related epilepsy. Seizures were uncontrolled on sodium valproate 1800 mg daily. He had a history of phenytoin-induced rash. Lamotrigine was introduced at 25 mg daily and 12 days later he developed an itchy maculo-papular rash over the inner aspect of both thighs. Lamotrigine was stopped immediately, the rash disappeared and the patient recovered completely.
Lamotrigine was reintroduced 2 years 11 months later at 12.5 mg on alternate days. The dose was gradually built up, over 6 months, with him obtaining excellent seizure control on 100 mg lamotrigine and 2000 mg sodium valproate daily without reapparance of the rash.
Case 5
Case 5 is a 23-year-old female with 20-year history of symptomatic generalized epilepsy. On sodium valproate 1000mg daily she was experiencing about two drop attacks daily and tonic-clonics daily. Lamotrigine was introduced at 25 mg b.d. with an initial significant reduction in seizure frequency. After 3 weeks the dose was increased from 150 mg to 200 mg daily and 2 days later she developed a vesicular and erythematous rash on her hands and legs with buccal ulceration but no genital ulceration. Full blood count was normal. Lamotrigine was discontinued. The rash worsened before completely fading by the ninth day. Lamotrigine was reintroduced at 25 mg daily dose, as an in-patient, 2 years later and the dose gradually increased over 4 weeks to 150 mg daily. There was no recurrence of the rash or mucosal ulceration and seizure frequency was significantly improved. Over the following 30 months of follow-up seizure improvement has been maintained with at most 10-15 drop attacks monthly and no further tonic-clonic seizures. However a mild fluctuating macular rash has been noted on and under her breasts, on her upper thighs, intrascapularly and over the outer ear canal and abdominal wall. This has not been associated with any haematological abnormality and never considered severe enough to warrant discontinuation of lamotrigine.
Case 6
Case 6 is a 49-year-old lady with 36-year history of localization-related epilepsy. Lamotrigine had been stopped due to a mild rash before admission to our practice and the nature of the rash and concomitant medication are not known to us. After admission, lamotrigine was reintroduced at 25 mg daily into her concomitant sodium valproate 1000 mg b.d. treatment. She was later discharged to her Primary Care Physician (General Practitioner, GP) with the same treatment. Her GP was informed to esca-late the daily dose by 25 mg every 2 weeks to a maximum dose of 200 mg daily but to discontinue the lamotrigine if she developed a rash. Six months later, her dose was successfuly increased to 75 mg b.d. without reappearance of the rash. Her seizure control had been good since restarting lamotrigine and the GP has not considered it necessary to increase the dose to 200 mg.
Case 7
Case 7 is a 6-year-old boy with 5.5 year history of symptomatic localization-related epilepsy. When he was in another hospital, lamotrigine was added to his treatment. Although the initial dose and concomitant medication are not known to us, within 10 days the dose had escalated to 100 mg b.d. and he had developed a morbilliform rash, lethargy, malaise and minor status. All drugs were stopped and he recovered. Fifteen months later, he was admitted to our practice and lamotrigine was reintroduced at 12.5 mg daily as monotherapy. The dose was gradually built up to 50 mg b.d. and he was discharged to his own GP. His GP successfully increased his dose to 100mg b.d. without reappearance of a rash.
Case 8
Case 8 is an 8-year-old boy with 5-year history of symptomatic localization-related epilepsy. His seizures were not controlled by clonazepam 3mg and sodium valproate 800mg daily. Lamotrigine was added to his treatment at the dose of 12.5 mg daily. He tolerated lamotrigine very well without any problems: Over the following 4 months the dose was gradually increased to 150 mg daily and sodium valproate was reduced and discontinued. Seven months later he developed a rash. It was suspected to be caused by lamotrigine and therefore lamotrigine was reduced from 150mg to 100mg. The rash then disappeared. Ten months later the dose of lamotrigine was increased to 125mg and the rash reappeared. Once again lamotrigine was reduced to 100mg and the rash disappeared. Four months later the dose was increased to 125mg again without the reappearance of the rash. The dose was then further increased to 250mg daily over the following 4 months without adverse effect.
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DISCUSSION
Although there is no experimental evidence that any rash was due to lamotrigine, we are unable to find alternative explanations in five cases. Two cases (cases 6 and 7) happened outside our practice and so we are unable to comment. It is possible that case 1 might be due to a concurrent viral infection.
All but two cases (case 8 and case 6) have shown a very good temporal relationship between development of the rash and lamotrigine administration, with the rash developing within a short period (<10 to 25 days) of lamotrigine administration and all patients recovering after drug withdrawal. These characteristics are very similar to those reported in other literature 2.
Drug-induced rash is normally regarded as a Type B reaction in that it cannot be predicted by the pharmacological action, and is normally not dose-dependent 4. However, it is recognized that a slower rate of introduction of lamotrigine decreases the likelihood of occurrence of skin rash 5 as has also been reported for phenytoin and carbamazepine s. Furthermore, cases 2 and 8 suggest the lamotrigine-related rash was dose or concentration-related.
Dollery has suggested that skin rashes attributed to lamotrigine hypersensitivity might simply be due to misinterpretation of an initial coincidental skin rash 7. Although we are not able to refute or support Dollery's suggestion, it seems unlikely that all reported successful rechallenging cases are due to misinterpretation of the initial skin rash.
As can be seen from Tables 1 and 2 initial introduction and rate of increase in cases 1, 2 and 5 would be considered high by current criteria 2. Case 4, with introduction at 25mg daily, was also above current guidelines in view of concomitant sodium valproate, but interestingly reintroduction at 25 mg daily in cases 5 and 6, also with concurrent sodium valproate, did not result in rash.
Initial rechallenge was above current guidelines for initial challenge for cases 5 and 6, within for case 1 and below for cases 2 and 4. Case 3 was particularly low as instead of a planned dose of 5 mg daily, 0.5 mg was administered instead.
The final dose reached varied below 75 mg to 200 mg total daily dose. In four cases (cases 2, 3, 4 and 7) the final dose equalled or exceeded the dose at which the rash had initially appeared. Additionally in case 8 the final dose also exceeded that at which the rashes had initially appeared. Other clinics than ours have also attempted to reintroduce lamotrigine to patients with a previous history of lamotrigine-induced rash. Schlumberger reintroduced lamotrigine to five children after the rash had disappeared s. In one child sodium valproate co-medication was maintained and the rash recurred 12 hours later. In the other four children lamotrigine was reintroduced after sodium valproate was discontinued and rechallenge was successful. Interestingly, in four of the eight cases we report lamotrigine was successfully reintroduced with concomitant sodium valproate.
The experiences from our practice and other centres s have demonstrated that it is possible to reintroduce lamotrigine to patients with a previous history of lamotrigine-related rash. However, clinicians have to balance the benefit and the risk, especially in the case of serious skin reactions such as Steven-Johnson syndrome and therefore we would recommend that reintroduction of lamotrigine should be done under close supervision.
